Why Anupam Rasayan Acquired Bliss GVS Pharma | Deputy CFO Vishal Thakkar Explains Strategy

By NDTV Profit

Community Score: 50% | 196 views | 5d

0 community ratings: null thumbs up, null thumbs down

Specialty chemicals company Anupam Rasayan India is set to acquire up to a 43.3% stake in Bliss GVS Pharma for an estimated ₹1,369.51 crore. The deal also includes an open offer for an additional 26% stake, strengthening Anupam Rasayan’s push into the pharmaceutical and CDMO space. The acquisition is expected to expand Anupam Rasayan’s presence across formulations, regulated markets, USFDA-approved facilities and global pharma supply chains. #AnupamRasayan #BlissGVS #StockMarketIndia #PharmaStocks #BusinessNews #Markets #CDMO #ChemicalStocks #ndtvprofitvideo #business Producer: Jinto Joy Anchor: Hiral Dadia Show: India Market Open For more videos subscribe to our channel: https://www.youtube.com/@NDTVProfitIndia Visit NDTV Profit for more news: https://www.ndtvprofit.com/ Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-reports Follow NDTV Profit here Twitter: https://twitter.com/NDTVProfitIndia , https://twitter.com/NDT

Tags: Anupam Rasayan, Bliss GVS Pharma, Anupam Rasayan acquisition, Bliss GVS deal, pharma acquisition India, stock market India, pharma stocks, specialty chemicals, Anupam Rasayan news, Bliss GVS news, open offer, CDMO business, pharmaceutical sector India, Indian stock market, business news, NDTV Profit, chemical stocks India, pharma manufacturing, USFDA plants, formulation business